Clinical characteristics and outcomes of Langerhans cell histiocytosis at a single institution in Thailand: a 20-year retrospective study
Ponrachet Kitticharoenjit
Profil Orcid, Nucharin Supakul
Profil Orcid, Piya Rujkijyanont
Profil Orcid, Chanchai Traivaree
Profil Orcid, Apichat Photia
Profil Orcid oraz Chalinee Monsereenusorn
Profil Orcid 
Kategoria artykułu: Original article
Data publikacji: 20 sie 2021
Zakres stron: 171 - 181
DOI: https://doi.org/10.2478/abm-2021-0022
Słowa kluczowe
© 2021 Ponrachet Kitticharoenjit et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Background
Langerhans cell histiocytosis (LCH) is a rare disease characterized by the various systems involved and clinical manifestations with a wide range of symptoms.
Objectives
To describe clinical characteristics, imaging, treatment, and outcomes of pediatric LCH at Phramongkutklao Hospital, Bangkok, Thailand.
Methods
We conducted a 20-year retrospective review of the medical records of patients diagnosed with LCH from birth to 21 years old from January 1, 1997, to December 31, 2016.
Results
In all, 14 patients with median age of 2.5 years were studied. Six (43%) patients had single-system (SS) LCH. Five patients (63%) with multisystem (MS) LCH (n = 8. 57%) had risk-organ involvement (RO+). All patients had plain X-ray imaging of their skull with 11 (79%) showing abnormal findings. Tc-99m bone imaging and fluorodeoxyglucose F18 (FDG) positron emission tomography (PET)-computed tomography (CT) demonstrated abnormal findings in 8 (89%) and 4 (29%) patients, respectively. The 5-year event-free survival (EFS) for patients with RO+ MS-LCH was less than that for those without risk-organ involvement (RO−) MS-LCH and SS-LCH (20% vs. 100%,
Conclusion
FDG-PET-CT might have a greater accuracy to detect LCH disease than conventional plain X-ray and Tc-99m bone imaging. RO+ MS-LCH has been encountered with relapse and poor outcomes. Hematopoietic involvement, hypoalbuminemia, and conjugated hyperbilirubinemia may be worse prognostic factors for RO+ MS-LCH.